At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets its products in more than 180 countries.
We build our company on the conviction that to be a sustainable business we must keep a balance sheet for three bottom lines – financial, social and environmental. We call this the Triple Bottom Line (TBL) business principle. It sets out how we manage our business with an ambition to be sustainable and account for performance in three dimensions.